Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial

Journal of Clinical Immunology

Volumn 35, Issue 4, 2015, Pages 399-407

  Lalazar, Gadi ^a,e   Mizrahi, Meir ^a   Turgeman, Ilit ^a   Adar, Tomer ^b   Ben Ya’acov, Ami ^a   Shabat, Yehudit ^a   Nimer, Assy ^d   Hemed, Nila ^a   Zolotarovya, Lidya ^a   Lichtenstein, Yoav ^a   Lisovoder, Nadya ^c   Samira, Sarit ^c   Shalit, Itamar ^c   Ellis, Ronald ^c   Ilan, Yaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c NasVax Ltd   (Israel)

^d Rebecca Sieff Government Hospital   (Israel)

^e MARION BESSIN LIVER RESEARCH CENTER   (United States)

Author keywords

anti CD3; NASH; oral tolerance

Indexed keywords

CD3 ANTIBODY; GLUCOSE; LATENCY ASSOCIATED PEPTIDE; LIPID; LIVER ENZYME; OKT 3; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; BIOLOGICAL MARKER; CYTOKINE;

ADULT; AGED; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE FUNCTION; FEMALE; FRACTURE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; INSULIN RESISTANCE; INTRAOCULAR HEMORRHAGE; LIMB PAIN; LIPID ANALYSIS; LIVER BIOPSY; LOW BACK PAIN; MALE; MUSCLE WEAKNESS; NAUSEA; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; REGULATORY T LYMPHOCYTE; SCLERA; SIDE EFFECT; UPPER ABDOMINAL PAIN; XEROSTOMIA; ADOLESCENT; ANIMAL; CLINICAL TRIAL; COMORBIDITY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; MOUSE; NON-ALCOHOLIC FATTY LIVER DISEASE; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANIMALS; BIOMARKERS; COMORBIDITY; CYTOKINES; FEMALE; HUMANS; IMMUNOPHENOTYPING; INSULIN RESISTANCE; MALE; MICE; MIDDLE AGED; MUROMONAB-CD3; NON-ALCOHOLIC FATTY LIVER DISEASE; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929839467     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-015-0160-6     Document Type: Article

References (34)

1. Friend PJ, Hale G, Chatenoud L, et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation. 1999;68:1632–7.
2. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3 gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54:1763–9.
3. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692–8.
4. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol. 2007;7:622–32.
5. Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994;265:1237–40.
6. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 2001;182:207–14.
7. Zhang X, Izikson L, Liu L, et al. Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol. 2001;167:4245–53.
8. Ishikawa H, Ochi H, Chen ML, et al. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes. 2007;56:2103–9.
9. Ochi H, Abraham M, Ishikawa H, et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med. 2006;12:627–35.
10. Rav-Acha M, Sassa D, Ilan Y, et al. [Surgical intervention in infective endocarditis: indications and timing]. Harefuah. 2005;144:421–5.
11. Wu HY, Quintana FJ, Weiner HL. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells. J Immunol. 2008;181:6038–50.
12. Wu HY, Maron R, Tukpah AM, et al. Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. J Immunol. 2010;185:3401–7.
13. Hotamisligil GS. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int J Obes (Lond). 2008;32 Suppl 7:S52–4.
14. Winer S, Chan Y, Paltser G, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15:921–9.
15. Ilan Y, Maron R, Tukpah AM, et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A. 2010;107:9765–70.
16. Ilan Y, Zigmond E, Lalazar G, et al. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol. 2010;30:167–77.
17. Renders L, Valerius T. Engineered CD3 antibodies for immunosuppression. Clin Exp Immunol. 2003;133:307–9.
18. Weiner HL, da Cunha AP, Quintana F, et al. Oral tolerance. Immunol Rev. 2011;241:241–59.
19. Meijer RT, Surachno S, Yong SL, et al. Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody. Clin Exp Immunol. 2003;133:485–92.
20. Saharinen J, Hyytiainen M, Taipale J, et al. Latent transforming growth factor-beta binding proteins (LTBPs)–structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev. 1999;10:99–117.
21. Verma SC, Lan K, Robertson E. Structure and function of latency-associated nuclear antigen. Curr Top Microbiol Immunol. 2007;312:101–36.
22. Oida T, Zhang X, Goto M, et al. CD4 + CD25- T cells that express latency-associated peptide on the surface suppress CD4 + CD45RB high-induced colitis by a TGF-beta-dependent mechanism. J Immunol. 2003;170:2516–22.
23. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–8.
24. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev. 2006;212:203–16.
25. Belkaid Y. Regulatory T, cells and infection: a dangerous necessity. Nat Rev Immunol. 2007;7:875–88.
26. Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev. 2006;212:217–37.
27. Shalev I, Schmelzle M, Robson SC, et al. Making sense of regulatory T cell suppressive function. Semin Immunol. 2011;23:282–92.
28. Bluestone JA, Tang Q. How do CD4 + CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol. 2005;17:638–42.
29. Chatenoud L, Bach JF. Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse. Int Rev Immunol. 2005;24:247–67.
30. Randolph DA, Fathman CG. Cd4 + Cd25+ regulatory T cells and their therapeutic potential. Annu Rev Med. 2006;57:381–402.
31. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol. 2007;7:988–94.
32. Yeh SH, Chuang H, Lin LW, et al. Tai chi chuan exercise decreases A1C levels along with increase of regulatory T-cells and decrease of cytotoxic T-cell population in type 2 diabetic patients. Diabetes Care. 2007;30:716–8.
33. Ma X, Hua J, Mohamood AR, et al. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology. 2007;46:1519–29.
34. Chatzigeorgiou A, Chung KJ, Garcia-Martin R, et al. Dual role of B7 costimulation in obesity-related nonalcoholic steatohepatitis and metabolic dysregulation. Hepatology. 2014;60:1196–210.